Relationship between endoscopic mucosal healing and histologic inflammation during remission maintenance phase in ulcerative colitis: a retrospective study

被引:29
|
作者
Kanazawa, Mimari [1 ]
Takahashi, Fumiaki [1 ,2 ]
Tominaga, Keiichi [1 ]
Abe, Keiichiro [1 ]
Izawa, Naoya [1 ]
Fukushi, Koh [1 ]
Nagashima, Kazunori [1 ]
Kanamori, Akira [1 ]
Takenaka, Kazuhiro [1 ]
Sugaya, Takeshi [1 ]
Iijima, Makoto [1 ]
Takada, Atsuko [3 ]
Imai, Yasuo [3 ]
Hiraishi, Hideyuki [1 ]
Irisawa, Atsushi [1 ]
机构
[1] Dokkyo Med Univ, Dept Gastroenterol, 880 Kitakobayashi, Shimotsuga, Tochigi 3210293, Japan
[2] Japanese Red Cross Ashikaga Hosp, Dept Internal Med, Ashikaga, Tochigi, Japan
[3] Dokkyo Med Univ, Dept Diagnost Pathol, Shimotsuga, Tochigi, Japan
关键词
QUALITY-OF-LIFE; BOWEL-DISEASE; 5-AMINOSALICYLIC ACID; PRACTICE GUIDELINES; CLINICAL RELAPSE; RISK-FACTOR; THERAPY; BIOPSY; MESALAZINE; INFLIXIMAB;
D O I
10.1055/a-0869-7619
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and study aims Recently, histological inflammation has been suggested to be an important predictor of sustained remission or relapse of ulcerative colitis (UC). In this study, we retrospectively compared severity of histological inflammation with endoscopic findings in UC patients with mucosal healing (MH) in the remission maintenance phase, and investigated whether histological healing could be a predictor of sustained remission. Patients and methods This study included 166 patients with MH in the remission maintenance phase. Endoscopic evaluation was based on the Mayo endoscopic subscore (MES), and MH was defined as MES 0 or 1. Severity of histological inflammation was graded according to the Matts classification. Patients with Matts 1 and 2 were included in the histological healing (HH) group, and those with Matts 3, 4, and 5, in the non-histological healing (NHH) group.In patients with MH, incidence of relapse was compared and analyzed according to severity of histological inflammation. Results The remission maintenance rate was significantly higher in the MES 0 group than in the MES 1 group ( P =0.004). The rate was significantly higher in the HH group than in the NHH group ( P =0.003). Within the MES 1 group, the rate was significantly higher in the HH subgroup than in the NHH subgroup ( P =0.030). Conclusions This retrospective study suggests that histological healing can be a predictor of sustained remission in UC patients, and examination of histological inflammation provides useful information for long-term management of UC, particularly in patients with MES 1.
引用
收藏
页码:E568 / E575
页数:8
相关论文
共 50 条
  • [11] Infliximab trough concentrations during maintenance therapy are associated with endoscopic and histologic healing in ulcerative colitis
    Papamichael, K.
    Rakowsky, S.
    Rivera, C.
    Cheifetz, A. S.
    Osterman, M. T.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 47 (04) : 478 - 484
  • [13] UPADACITINIB PROMOTES HISTOLOGIC AND ENDOSCOPIC MUCOSAL HEALING: RESULTS FROM THE UPADACITINIB ULCERATIVE COLITIS PHASE 3 PROGRAM
    Peyrin-Biroulet, Laurent
    Siegel, Corey A.
    Tanida, Satoshi
    Bossuyt, Peter
    Torres, Esther A.
    Dubinsky, Marla
    Baerl, Filip J.
    Zhou, Wen
    Klaff, Justin
    Berg, Sofie
    Laroux, Stephen
    Gonzalez, Yuri Sanchez
    Yao, Xuan
    Zhou, Qing
    Reinisch, Walter
    GASTROENTEROLOGY, 2022, 162 (07) : S978 - S978
  • [14] Upadacitinib Promotes Histologic and Endoscopic Mucosal Healing: Results from the Upadacitinib Ulcerative Colitis Phase 3 Program
    Peyrin-Biroulet, L.
    Siegel, C.
    Tanida, S.
    Bossuyt, P.
    Torres, E.
    Dubinsky, M.
    Baert, F.
    Zhou, W.
    Klaff, J.
    Berg, S.
    Laroux, F. S.
    Gonzalez, Y. Sanchez
    Yao, X.
    Zhou, Q.
    Reinisch, W.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I477 - I478
  • [15] Upadacitinib Promotes Histologic and Endoscopic Mucosal Healing: Results from the Upadacitinib Ulcerative Colitis Phase 3 Program
    Peyrin-Biroulet, L.
    Siegel, C.
    Tanida, S.
    Bossuyt, P.
    Torres, E.
    Dubinsky, M.
    Baert, F.
    Zhou, W.
    Klaff, J.
    Berg, S.
    Laroux, F. S.
    Gonzalez, Y. Sanchez
    Yao, X.
    Zhou, Q.
    Reinisch, W.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I477 - I478
  • [16] Endoscopic mucosal healing and histologic remission in ulcerative colitis: a systematic literature review of clinical, quality-of-life and economic outcomes
    Pandey, Anuja
    Achrafie, Lea
    Kodjamanova, Petya
    Tencer, Tom
    Kumar, Jinender
    CURRENT MEDICAL RESEARCH AND OPINION, 2022, 38 (09) : 1531 - 1541
  • [17] Association of golimumab trough concentrations during maintenance with clinical, biological, endoscopic and histologic remission in patients with ulcerative colitis
    Taxonera, Carlos
    Fernandez-Acenero, Maria Jesus
    Olivares, David
    Calvo, Marta
    Casis, Begona
    Bermejo, Fernando
    Serrano, Pilar Lopez
    Iborra, Marisa
    Mesonero, Francisco
    Watts, Maia Bosca
    del Arco, Cristina Diaz
    Vera, Isabel
    Olivares, Sonsoles
    Algaba, Alicia
    Alba, Cristina
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 56 (04) : 614 - 624
  • [18] Directionality of endoscopic and histologic healing in ulcerative colitis: a prospective pilot study
    Hanzel, Jurij
    Novak, Gregor
    Jairath, Vipul
    Zou, Guangyong
    Dong, Hannah
    Gui, Xianyong
    Hindryckx, Pieter
    Beaton, Melanie
    Bressler, Brian
    Lowenberg, Mark
    Panaccione, Remo
    D'Haens, Geert
    Feagan, Brian
    Ma, Christopher
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2025, 37 (03) : 304 - 307
  • [19] ASSOCIATION OF HISTOLOGIC-ENDOSCOPIC MUCOSAL HEALING AFTER USTEKINUMAB INDUCTION OR MAINTENANCE THERAPY WITH 2-YEAR OUTCOMES IN THE UNIFI PHASE 3 STUDY IN ULCERATIVE COLITIS
    Li, Katherine
    Yang, Feifei
    Marano, Colleen W.
    Zhang, Hongyan
    Sandborn, William J.
    Sands, Bruce E.
    Feagan, Brian G.
    Rubin, David T.
    Peyrin-Biroulet, Laurent
    Friedman, Joshua
    De Hertogh, Gert
    GASTROENTEROLOGY, 2020, 158 (06) : S1192 - S1192
  • [20] Association of histologic-endoscopic mucosal healing after ustekinumab induction or maintenance therapy with 2-year outcomes in the UNIFI Phase 3 study in ulcerative colitis
    Li, K.
    Yang, F.
    Marano, C.
    Zhang, H.
    Sandborn, W. J.
    Sands, B. E.
    Feagan, B. G.
    Rubin, D. T.
    Peyrin-Biroulet, L.
    Friendman, J. R.
    De Hertogh, G.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S574 - S575